Combination of vascular targeting agents with thermal or radiation therapy.
about
Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor modelsNanoparticle preconditioning for enhanced thermal therapies in cancerVascular disrupting agent arsenic trioxide enhances thermoradiotherapy of solid tumors.Combretastatin A4 phosphate: background and current clinical status.Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.Selective targeting of the tumour vasculature.The effect of mild temperature hyperthermia on tumour hypoxia and blood perfusion: relevance for radiotherapy, vascular targeting and imaging.Imaging tumour physiology and vasculature to predict and assess response to heat.Realistic biological approaches for improving thermoradiotherapy.Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates.Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours.Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation.Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy.Targeting tumour hypoxia to improve outcome of stereotactic radiotherapy.The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
P2860
Q26781365-E927AFB5-8F29-4745-BA70-801A33B0AF06Q28543671-F096C3E2-6D96-43BD-A5A6-B6FB783C5F67Q34987068-AF8D35D5-3285-488B-98FF-2F836C1FC3D9Q35681405-89545D02-5379-4AFC-A732-285BC328D384Q35871932-636C3DC8-2126-4716-A08A-BCA66F37C656Q36433061-49340784-1E5B-46FD-A5E7-00371129211CQ37311351-0B422C8F-B448-4A34-9434-9C983D0B6958Q37709394-C819F591-7636-4D8E-9F9E-447FD5D244A0Q37730090-E1CF2F37-8621-499A-8AE5-0670792C3EBBQ38648236-56EC1B77-A2B9-48E6-8C9D-DC8065B28D7CQ39173092-F5DDA8FA-8861-44F5-872F-E77E773E8ED8Q39657204-AC8BDFF0-51A9-4A57-B61E-719FC7C2B629Q40593312-41E57935-0FFB-4408-AB8F-3D4DBD7FB9DBQ44942124-D438AF80-EF69-40B8-A12A-8C056EE5F810Q46882346-63672435-7680-4649-8D34-B7DC8AF6E2D5Q51029869-9BED3DB1-3FBE-4183-B7EC-6C468D1D0500Q51210513-5841F928-5CC4-4711-B2B0-7EF244A63716Q51598914-1B678139-005C-46B1-9CA2-ED2131BA4E47Q51808119-F6930C70-5AD4-460B-9E32-43920F4A1CE0
P2860
Combination of vascular targeting agents with thermal or radiation therapy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Combination of vascular targeting agents with thermal or radiation therapy.
@en
Combination of vascular targeting agents with thermal or radiation therapy.
@nl
type
label
Combination of vascular targeting agents with thermal or radiation therapy.
@en
Combination of vascular targeting agents with thermal or radiation therapy.
@nl
prefLabel
Combination of vascular targeting agents with thermal or radiation therapy.
@en
Combination of vascular targeting agents with thermal or radiation therapy.
@nl
P1476
Combination of vascular targeting agents with thermal or radiation therapy.
@en
P2093
Rumi Murata
P304
P356
10.1016/S0360-3016(02)03926-3
P407
P577
2002-12-01T00:00:00Z